This Week in Urology — Jul 31, 2026

Welcome to This Week in Urology. This week we are covering ten notable papers spanning new clinical guidelines, updates in urologic oncology, and innovations in endourology and functional urology. Let us dive in.

We start with a major landmark release in endourology: the updated 2026 American Urological Association guidelines on the medical management of kidney stones, published in The Journal of Urology [1], [2]. This comprehensive two-part guideline updates our framework for the metabolic evaluation, dietary management, and pharmacologic treatment of patients with a history of nephrolithiasis to prevent recurrence. Part I focuses on patient evaluation and dietary strategies, emphasizing that metabolic testing should be offered to high-risk or highly motivated patients, with dietary interventions tailored to specific stone compositions [1]. Part II details pharmacologic therapies and active surveillance strategies [2]. In a closely related development in surgical stone management, a systematic review and meta-analysis published in the BJU International compared contemporary flexible and navigable suction access sheath-assisted retrograde intrarenal surgery, or FANS-RIRS, against mini-percutaneous nephrolithotomy for large upper urinary tract stones between two and three centimeters [5]. Analyzing ten studies and over twenty-three hundred patients, the authors found that FANS-RIRS achieved stone-free rates and ancillary procedure rates comparable to mini-percutaneous nephrolithotomy. However, the retrograde approach was significantly safer, showing smaller declines in hemoglobin, lower transfusion rates, and shorter hospital stays, though mini-percutaneous nephrolithotomy maintained a shorter operative time. When retrograde access is needed in an outpatient setting, a systematic review from the European Association of Urology Endourology group in the World Journal of Urology evaluated retrograde ureteral stenting under local anesthesia in nearly two thousand patients [7]. They reported an overall technical success rate of eighty-nine percent, which was highest for stone-related obstructions at ninety-four percent but dropped to eighty-two percent for malignant obstructions. Crucially, the review identified key predictors of outpatient stenting failure, including bladder trigone or distal ureteric invasion, severe hydronephrosis, and a poor performance status of ECOG two or greater. This provides clinicians with a practical framework for selecting patients who can safely undergo local anesthesia stenting versus those who require the operating room or percutaneous drainage.

Moving into urologic oncology, several key papers this week challenge current paradigms in prostate, bladder, and kidney cancer management. In prostate cancer, a major individual patient data meta-analysis of five randomized phase three trials involving over forty-seven hundred patients was published in European Urology [3]. The investigators examined whether adverse pathological features, such as high grade group, seminal vesicle invasion, positive surgical margins, or extracapsular extension, could predict who benefits from adding hormone therapy to postoperative radiotherapy in patients with a low pre-radiation prostate-specific antigen of zero-point-five nanograms per milliliter or less. While the count of adverse pathological features was independently prognostic for overall survival and metastasis-free survival, it did not significantly modify the benefit of adding hormone therapy. This suggests that these adverse features, while useful for prognosis, should not be used as predictive biomarkers to select or omit hormone therapy in this low prostate-specific antigen setting. In bladder cancer, a multi-institutional retrospective cohort study in European Urology Focus looked at the correlation between local bladder response and pelvic lymph node status after neoadjuvant chemotherapy in over seven hundred patients undergoing radical cystectomy [4]. Although achieving a complete pathological response in the bladder or downstaging to non-muscle-invasive disease was associated with lower odds of nodal involvement, five percent of patients with a completely clear bladder and ten percent of downstaged patients still harbored residual lymph node metastases. This discordant response highlights that clinical and radiological variables cannot reliably exclude nodal disease, urging extreme caution when considering bladder-sparing strategies based solely on local response. For patients who do proceed to radical cystectomy, a large meta-analysis in the World Journal of Urology compared robot-assisted radical cystectomy with intracorporeal urinary diversion against open radical cystectomy in over eight thousand patients [6]. The robotic approach demonstrated superior perioperative outcomes, including lower blood loss, shorter hospital stays, more lymph nodes removed, and fewer short-term complications. However, clinicians must note that the robotic approach carried a significantly higher risk of ureteroenteric strictures, and the observed improvements in five-year overall and cancer-specific survival must be interpreted with caution due to the observational nature of the included studies. Finally, in renal cell carcinoma, a retrospective study of over four hundred patients in the International Journal of Urology explored preoperative predictors of upstaging in clinical T1 disease [9]. The authors found that preoperative tumor shape irregularity on computed tomography was a powerful independent predictor of pathological upstaging to pT3. Compared to regular tumors, moderately irregular tumors had over five times the odds of upstaging, while highly irregular tumors had over thirty times the odds of upstaging. This simple radiological assessment of tumor shape can significantly aid preoperative risk counseling, particularly when planning nephron-sparing surgery.

In functional urology and benign prostatic hyperplasia, two studies offer valuable clinical insights. First, a prospective cohort study published in the World Journal of Urology evaluated whether prostate size affects the outcomes of Aquablation for benign prostatic hyperplasia [8]. Comparing over six hundred men with prostate volumes either below or above eighty cubic centimeters, the researchers found that both groups achieved substantial and durable improvements in urinary symptoms and quality of life at twenty-four months. Although men with larger prostates had longer operative times and hospital stays, high-grade complications and reoperation rates remained low and comparable between the groups, and sexual function was well preserved. This supports Aquablation as a highly effective, size-independent surgical option. For overactive bladder, a narrative review in the World Journal of Urology assessed the clinical and real-world evidence for transcutaneous tibial nerve stimulation, or TTNS [10]. Synthesizing data from twenty-eight prospective studies, the review reported a mean responder rate of over seventy-two percent, with significant benefits over sham for non-neurogenic overactive bladder. While TTNS was generally less effective than anticholinergic medications, it was markedly better tolerated and proved non-inferior to percutaneous tibial nerve stimulation in a randomized controlled trial, positioning it as a highly patient-friendly, non-invasive option in our therapeutic arsenal.

If you only have time for one paper this week, make it the multi-institutional study on discordant lymph node responses in bladder cancer, published in European Urology Focus [4]. This paper provides a critical reality check for bladder-sparing protocols by demonstrating that five percent of patients with a complete pathological response in the bladder still harbor pelvic lymph node metastases, proving that we cannot yet rely on local response alone to omit nodal clearance.

Here are the key takeaways from this week in Urology. First, when managing kidney stones, use the newly updated AUA guidelines to guide metabolic and dietary strategies, and consider flexible and navigable suction access sheath-assisted retrograde intrarenal surgery as a safe and highly effective alternative to mini-percutaneous nephrolithotomy for stones up to three centimeters. Second, be aware that outpatient ureteral stenting under local anesthesia has a high success rate but is more likely to fail in patients with bladder trigone invasion, severe hydronephrosis, or poor performance status. Third, do not use adverse pathological features to decide on adding hormone therapy to postoperative radiation in low prostate-specific antigen recurrences, as these features do not predict hormone therapy benefit. Fourth, counsel patients undergoing robotic intracorporeal radical cystectomy about its superior recovery profile but highlight the increased risk of ureteroenteric stricture compared to open surgery. And finally, evaluate preoperative tumor shape irregularity on computed tomography scans for clinical T1 renal masses, as irregular borders are strongly associated with pathological upstaging to pT3.

That is your roundup for This Week in Urology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.